Announcements Trials
Browse Landscape

Phase

Phase 2 39Phase 3 7Phase 4 4Phase 2/3 3Phase NA 2Phase 1 2

Status

Unknown 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Breast 1

Conditions

Quality of Life 1Lung Neoplasms 1Breast Neoplasms 1

Interventions

Cisplatin 20Docetaxel 19Capecitabine 19Oxaliplatin 14Drug Therapy 14Cyclophosphamide 14Paclitaxel 13Fluorouracil 12Radiotherapy 11apatinib 9Gemcitabine 9Doxorubicin 9Decitabine 9Methotrexate 8Epirubicin 8Carboplatin 8sintilimab 6Etoposide 6camrelizumab 5anlotinib 5XELOX 5Sorafenib 5Radiation 5Pemetrexed 5Neoadjuvant Therapy 5Leucovorin 5Idarubicin 5Dexamethasone 5Cytarabine 5Busulfan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Unknown × endostar protein × Clear all
NCT01907529 2019-08-09

TENDENCY

Hebei Medical University Fourth Hospital

Phase 2/3 Unknown
300 enrolled
Breast

Breast Neoplasms

NCT03588494 2018-07-17

Endostar in Combination With Chemoradiotherapy in Patient With Advanced Non-small Cell Lung Cancer

Affiliated Hospital of North Sichuan Medical College

Phase 2/3 Unknown
318 enrolled

Quality of Life

NCT02350361 2015-01-29

Endostar Combination With Chemotherapy and EGFR-TKI in Lung Cancer Rechallenging Treatment After Acquired Resistance.

Peking University Third Hospital

Phase 2/3 Unknown
60 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡